Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Dyne Readies DMD Exon-Skipper For Filing, Could Be Competitive With Sarepta Drug
BLA Filing Planned For Q2 2026
Dec 08 2025
•
By
Mandy Jackson
Dyne's DMD drug performed better than placebo across six functional measures
(Shutterstock)
Keep up with the top pharma business news of the week. On the go.
Scrip brings you a weekly bulletin of top picks.
More from Clinical Trials
More from R&D